I reckon that if someone is somehow able to invent and trial a new FTO inhibitor ahead of Xantrene (which is massively unlikely) then someone else will instantly snap up Xantrene to ensure they're quickly to market - so it's a win either way.
Alternatively, IMHO should someone even get one into the clinic then someone else will rush Xantrene to get to market first.
A friend of mine strategised this last May, and I tend to agree with him.
Ann: Trading Halt, page-87
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.65 |
Change
-0.095(5.44%) |
Mkt cap ! $281.0M | |||
| Open | High | Low | Value | Volume |
| $1.78 | $1.78 | $1.62 | $285.9K | 170.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 16759 | $1.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.69 | 12047 | 1 |
View Market Depth
| Last trade - 16.10pm 03/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |